The pharmaceutical and bio sectors are grappling with a 'triple challenge' due to drug price reductions, increased regulatory scrutiny, and a resulting decline in investor sentiment.
According to industry sources, the government has implemented a reform of the drug pricing system starting this month, lowering the maximum price calculation rate for generic and off-patent drugs from 53.55% to 45% of the original drug price. Existing high-priced drugs will be adjusted gradually, while new generics will receive certain advantages based on whether they are certified as innovative or quasi-innovative pharmaceutical companies.
Concerns are growing that this measure will directly pressure the profitability of small and mid-sized pharmaceutical companies and burden those heavily reliant on contract sales organizations (CSOs). If the revenue structure centered on generics is disrupted, the capacity for research and development (R&D) investment will inevitably decline. As the traditional growth model of expanding product lines hits its limits, this price reduction is expected to catalyze a restructuring across the industry.
The impact has been exacerbated by the tightening of disclosure regulations. The Financial Supervisory Service (FSS) has overhauled the disclosure system for pharmaceutical and bio companies, requiring them to present key assumptions for valuing their businesses—such as clinical trial success rates, approval and review risks, development timelines and costs, and expected market sizes—in a standardized manner. Technology transfer agreements must also separate and disclose contract amounts, milestones, and royalties.
The FSS plans to extend its oversight beyond disclosures to include press releases and media interviews. It aims to prevent the inclusion of undisclosed important information in press releases or providing information to the media that differs from official disclosures. While the industry agrees with the intent to reduce exaggerated promotions, there are concerns that this could stifle normal explanations of future value.
Historically, the bio sector has been driven by the announcement of clinical data, technology transfer agreements, and expectations of approvals, which have influenced stock prices and funding. However, with authorities now demanding that these expectations be backed by quantifiable and verifiable information, attracting investors solely through 'dream drugs' and 'major technology exports' has become more challenging.
Kim Seon-a, a researcher at Hana Financial Investment, expressed concern that the revised disclosure standards requiring the separation of total contract sizes, upfront payments, conditional milestones, and royalties could impact future contract terms with other partners. She cautioned, "Important contracts should not be delayed or lost due to the need for disclosures."
A chill in the initial public offering (IPO) market is also anticipated due to declining investor sentiment. With the bio investment climate weakening in the second half of the year and the tightening of disclosure regulations, subsequent listings and funding for bio companies may become increasingly difficult.
An industry insider noted, "A sorting process will begin where only companies with R&D capabilities and global competitiveness will survive. However, it is essential to ensure that the industrial ecosystem does not become excessively stifled during this process."
According to industry sources, the government has implemented a reform of the drug pricing system starting this month, lowering the maximum price calculation rate for generic and off-patent drugs from 53.55% to 45% of the original drug price. Existing high-priced drugs will be adjusted gradually, while new generics will receive certain advantages based on whether they are certified as innovative or quasi-innovative pharmaceutical companies.
Concerns are growing that this measure will directly pressure the profitability of small and mid-sized pharmaceutical companies and burden those heavily reliant on contract sales organizations (CSOs). If the revenue structure centered on generics is disrupted, the capacity for research and development (R&D) investment will inevitably decline. As the traditional growth model of expanding product lines hits its limits, this price reduction is expected to catalyze a restructuring across the industry.
The impact has been exacerbated by the tightening of disclosure regulations. The Financial Supervisory Service (FSS) has overhauled the disclosure system for pharmaceutical and bio companies, requiring them to present key assumptions for valuing their businesses—such as clinical trial success rates, approval and review risks, development timelines and costs, and expected market sizes—in a standardized manner. Technology transfer agreements must also separate and disclose contract amounts, milestones, and royalties.
The FSS plans to extend its oversight beyond disclosures to include press releases and media interviews. It aims to prevent the inclusion of undisclosed important information in press releases or providing information to the media that differs from official disclosures. While the industry agrees with the intent to reduce exaggerated promotions, there are concerns that this could stifle normal explanations of future value.
Historically, the bio sector has been driven by the announcement of clinical data, technology transfer agreements, and expectations of approvals, which have influenced stock prices and funding. However, with authorities now demanding that these expectations be backed by quantifiable and verifiable information, attracting investors solely through 'dream drugs' and 'major technology exports' has become more challenging.
Kim Seon-a, a researcher at Hana Financial Investment, expressed concern that the revised disclosure standards requiring the separation of total contract sizes, upfront payments, conditional milestones, and royalties could impact future contract terms with other partners. She cautioned, "Important contracts should not be delayed or lost due to the need for disclosures."
A chill in the initial public offering (IPO) market is also anticipated due to declining investor sentiment. With the bio investment climate weakening in the second half of the year and the tightening of disclosure regulations, subsequent listings and funding for bio companies may become increasingly difficult.
An industry insider noted, "A sorting process will begin where only companies with R&D capabilities and global competitiveness will survive. However, it is essential to ensure that the industrial ecosystem does not become excessively stifled during this process."
* This article has been translated by AI.
Copyright ⓒ Aju Press All rights reserved.